Lunit touts studies to be presented at SITC meeting

Lunit noted that six studies featuring the use of its AI technology will be presented at the Society for Immunotherapy of Cancer (SITC) 2023 meeting being held November 1 to 5 in San Diego.

The studies highlight the predictive value and analytical power of the company’s Lunit SCOPE suite in various types of cancer, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer, Lunit said.

Lunit’s SCOPE IO software analyzes a patient’s cancer tissue slide image by observing the distribution of tumor-infiltrating lymphocytes, which fight cancer cells. Based on the spatial distribution pattern of tumor-infiltrating lymphocytes, the software may help clinicians identify patients at higher risk, the company said.

Page 1 of 361
Next Page